Abstract
Although the efficacy of radionuclide therapy has been demonstrated in several indications, the development of this new therapeutic modality is limited. However, promising results have been obtained, especially using different radiolabeled somatotatin analogs for neuroendocrine tumors or radioimmunotherapy for lymphoma. Toxicity is limited, particularly if patients are selected based on their background. The use of new vectors (bombesin, anti-PMSA monoclonal antibody), pretargeting system and innovative radionuclides (Copper-67, Astatine-211) suggests interesting perspectives, particularly to target small tumor masses or residual disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
